Clarivate 2026 Q2 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Clarivate reported Q2 2026 revenue of $587 million and H1 revenue of nearly $1.2 billion, with organic ACV growth improving to 1.5%.
- Profit margin expanded to more than 42% at the segment level, with academia and government and life sciences and health each delivering 2% organic ACV growth.
- Net loss in Q2 was $269 million, driven by a non-cash impairment charge related to the agreement to divest the Life Science and Health segment.
- Adjusted diluted EPS in Q2 was $0.19, up a cent year over year, with H1 EPS at $0.38, a 19% increase over last year.
- Operating cash flow was $99 million in Q2, with free cash flow at $44 million, down $6 million from last year due to working capital timing.
- Clarivate repurchased $75 million of bonds in the first half, reducing debt by $218 million.
- The company announced the agreement to sell its Life Science and Health segment to Altoros, expected to close by year-end.
- Recurring organic revenue in the intellectual property segment improved to flat in Q2, with expectations to return to growth in the second half.
- Clarivate launched new AI products including Web of Science Research Intelligence, Nexus Connect, and IP one, enhancing AI-driven offerings.
- Risk Mark, an AI tool for lawyers, won the 2026 Codie Award for best AI tool and was previously named Legal Tech Predictive AI Solution of the Year in 2025.
- Michael Easton was appointed CFO effective August 8, succeeding Jonathan Collins who will depart after significant contributions.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Your first question comes from the line of Scott Wurtzel with Wolfe Research. Your line is open. Please go ahead.
Hey, guys. Good morning, and thank you for taking my questions. Just wanted to touch on, you guys cited some timing around renewals that may have impacted ACV growth during the quarter. Is anything around that due to longer sales cycles, and anything we should expect to persist at all in the second half of the year?
Hey, good morning, Scott. Thanks for the question. We believe that our results for Q2 and the first half are in line with our original expectations. If I remind everyone, we pointed the equivalent of page 20 in Q1 indicated we expected to see a pullback in recurring organic growth in Q2. Subscriptions were a part of that. ACV, we continue to make progress over the last six quarters. It's not always going to be linear, but we continue to see strong renewal rates, and good opportunities for the new products to convert to sales. The timing of renewals is something we see in the business from time to time, though we don't think it's an elongation of the renewal cycle.
The organic ACV growth of about a percent and a half in the end of June is generally in line with our first half organic growth for subscription revenues at about 1.2%. We're generally where we expected, and as we indicate also on page 20 in this quarter's tack, we expect the ACV and the organic recurring revenue to inflect in the second half of the year. We have good line of sight to that. At this point in the year, the A&G business as of the end of July has 75% of this year's business in the bag. Very similar to what we saw at this point last year. The fall's an important renewal cycle, but we're already well on our way, and we have good line of sight for the second half of the year. Thanks for the question, Scott.
Your next question comes from the line of Toni Kaplan with Morgan Stanley. Your line is open. Thank you.
Thanks so much. I was hoping you could talk more about the MCP opportunity, where you think which client types are going to more gravitate towards utilizing your data over MCP, which segments, et cetera. Just how you're thinking about how it could contribute to growth, and is it included in the subscription or is there an upcharge for it? Also just, Jonathan, congratulations on your new opportunity. Thanks. I'll take this one.
Thank you, Toni. To maybe take a broader view on the AI innovation we are doing, we are very much focused, and since I joined or since we started the VCP, we are delivering on 19 different initiatives regarding external and new product that we are delivering. We are very pleased with the progress so far, which is the AI enablement of our existing product is a source of revenue for new logos, new products, and improving retention. I think also to allow us to have some AI-specific pricing for new products. New revenue generation or new revenue stream. For example, Web of Science Research Intelligence, definitely a new revenue stream. Harmaspecto, a new revenue stream. IPOne that I've been talking about, and we are very excited about IPOne, definitely a new revenue stream.
Some will come, Nexus Connect, another product from A&G which involve MCP, and we see the customers industry segment including the life science, how they want to consume our data, our proprietary data. Either directly through us with our UX or a new AI-enabled product, or using their own customers. There's a tendency in some the bigger customer, who would like us to embed our capabilities, the MCP capabilities, into their respective corporate AI product. This is why you see more of our product, whether it's embedded into Anthropic, ChatGPT, and other generic LLMs. By and large, the bigger customer would like to be able to embed this through MCP. Smaller customer may want to use it in our environment, but this is just early days.
Overall, we are very pleased with the momentum that we have in introducing AI, either our own native or embedding our proprietary data into MCP environment of the customer designation corporate AI infrastructure.
Thank you. Your next question comes from the line of Manav Patnaik with Barclays.
Your line is open. Please go ahead.
Thank you. First, congratulations, Jonathan and Mike, both, for your new roles. I just had a question on the expectation for acceleration of organic growth. I think you said sequentially 100 basis points. Can you flesh that out a bit if it's different between academic and government and then the IP side as well? I think just going into 2027, I guess maybe just is that 100 basis points for the full year as well in 2027, or how we should think about that?
I think we are pretty positive on both segments. We have a line of sight that the momentum is building up in IP as well. We are back to recurring flat in Q2. We believe that we're going to improve recurring in the second half of the year for IP as well, with a great new momentum. Here to re-mention the introduction of, or the rejoining of Simon to Clarivate. He's been in the industry for 20 years. He was kind enough to come back and support us. He will utilize all his IP knowledge and expertise in accelerating the progress on the IP turnaround. We do believe IP will be turned around faster with Simon in place, and with the great assets, annuity, software intelligence that we have, and with the AI innovation I've mentioned.
I've mentioned RiskMark as a product that won three awards. I'm also upbeat about IPOne. IPOne is not just intelligence. IPOne is in fact an agentic environment in which IP professional. Basically, we're taking a different route. We all know about the data winds and the other one, which has been a little bit contracting. Basically, we are going to disrupt the market using both our agentic capabilities and expertise and our proprietary data. That's on the IP side. On the A&G side, momentum is also building with the new Web of Science Research Intelligence, with the new Harmaspecto, and with obviously Nexus Connect, and some of the new innovation coming out from the A&G product hubs. Optimistic on both ends. Your next question.
Next question, please. Your next question comes from the line of George Tong with Goldman Sachs.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
9 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
